WMS 2023 poster presentation: Pulmonary function in patients with Duchenne muscular dystrophy from the STRIDE Registry and the CINRG Natural History Study: A matched cohort analysis
This poster presentation, developed as part of WMS 2023, explores data from the STRIDE Registry and CINRG Natural History Study to assess the effect of mutation-specific treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD) on pulmonary function
Explore the patient demographics for the STRIDE Registry and CINRG Natural History Study
Compare results from 2 groups of patients who received either combined mutation-specific treatment for nmDMD with standard of care (SoC), or SoC alone
Discover the pulmonary functioning outcomes for each patient group, measured by age at <60% and <50% predicted forced vital capacity
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at email@example.com.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
This poster presentation was developed and funded by PTC Therapeutics for WMS 2023.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2300184 | January 2024
Sign in or register to access exclusive content on this site